Role of dietary fibres, intestinal hypermotility and leukotrienes in the pathogenesis of NSAID-induced small intestinal ulcers in cats

Gut

Volumn 58, Issue 12, 2009, Pages 1590-1596

  Satoh, H ^a   Shiotani, S ^a   Otsuka, N ^a   Hatao, K ^a   Nishimura, S ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; CIMETIDINE; COLESTYRAMINE; DOCEBENONE; ERYTHROMYCIN; INDOMETACIN; LEUKOTRIENE; NEOMYCIN; PRANLUKAST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIETARY FIBER; DRUG EFFECT; EXPERIMENTAL CAT; FEMALE; INTESTINAL DYSMOTILITY; INTESTINE ULCER; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; TELEMETRY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CATS; DIET; DIETARY FIBER; DUODENAL ULCER; EATING; FEMALE; GASTROINTESTINAL MOTILITY; ILEUM; INDOMETHACIN; INTESTINAL DISEASES; INTESTINE, SMALL; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; MALE; ULCER;

EID: 72549093722     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2008.156596     Document Type: Article

References (38)

1. Brodie DA, Cook PG, Bauer BJ, et al. Indomethacin-induced intestinal lesions in the rats. Toxicol Appl Pharmacol 1970;17:615-624
2. Langman MJS, Morgan L, Worrall A. Use of anti-inflammatory drugs by patients admitted with small or large bowel perforations and haemorrhage. Br Med J 1985;290:347-349 (Pubitemid 15115450)
3. Bjarnason I, Zanelli G, Smith T, et al. Nonsteroidal anti-inflammatory drug-induced intestinal inflammation in humans. Gastroenterology 1987;93:480-489 (Pubitemid 17119242)
4. Allison MC, Howatson AG, Torrance CJ, et al. Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs. N Engl J Med 1992;327:749-754
5. Laine L, Connors LG, Reicin A, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003;124:288-292 (Pubitemid 36169245)
6. Maiden L, Thjodleifsson B, Theodors A, et al. A quantitative analysis of NSAIDinduced small bowel pathology by capsule enteroscopy. Gastroenterology 2005;128:1172-1178
7. Goldstein JL, Eisen GM, Lewis B, et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroent Hepatol 2005;3:133-141 (Pubitemid 40220308)
8. Fortun PJ, Hawkey CJ. Nonsteroidal anti-inflammatory drugs and the small intestine. Curr Opin Gastroenterol 2007;23:134-141 (Pubitemid 46192967)
9. Neiger R. NSAID-induced gastrointestinal adverse effects in dogs - Can we avoid them? J Vet Intern Med 2003;17:259-261
10. Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: The second hundred years. Gastroenterology 1997;112:1000-1016
11. Whittle BRJ. Mechanisms underlying intestinal injury induced by anti-inflammatory COX inhibitors. Eur J Pharmacol 2004;500:427-439
12. Lanas Á, Scarpignato C. Microbial flora in NSAID-induced intestinal damage: A role for antibiotics? Digestion 2006;73(Suppl 1):136-150
13. Lichtenberger LM, Zhou Y, Dial EJ, et al. NSAID injury to the gastrointestinal tract: evidence that NSAIDs interact with phospholipids to weaken the hydrophobic surface barrier and induce the formation of unstable pores in membrane. J Pharm Pharmacol 2006;58:1421-1428 (Pubitemid 44785529)
14. Wallace JL, McKnight W, Reuter BK, et al. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000;119:706-714 (Pubitemid 30681131)
15. Tanaka A, Hase S, Miyazawa T, et al. Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage. J Pharmacol Exp Ther 2002;300:754-761 (Pubitemid 34164976)
16. Rainsford KD. The effects of 5-lipoxygenase inhibitors and leukotriene antagonists on the development of gastric lesions induced by nonsteroidal anti-inflammatory drugs in mice. Agents Actions 1987;21:316-319
17. Rainsford KD. Inhibition by leukotriene inhibitors, and calcium and platelet-activating factor antagonists, of acute gastric and intestinal damage in arthritic rats and in cholinomimetic-treated mice. J Pharm Pharmacol 1999;51:331-339
18. Takeuchi K, Miyazawa T, Tanaka A, et al. Pathogenic importance of intestinal hypermotility in NSAID-induced small intestinal damage in rats. Digestion 2002;66:30-41. (Pubitemid 36151288)
19. Takeuchi K, Tanaka R, Ohno R, et al. Role of COX inhibition in pathogenesis of NSAID-induced small intestinal damage. J Physiol Pharmacol 2003;54(Suppl 4):165-182
20. Tanaka A, Matsumoto M, Hayashi Y, et al. Functional mechanism underlying cycloxygenase-2 expression in rat small intestine following administration of indomethacin: Relation to intestinal hypermotility. J Gastroenterol Hepatol 2005;20:38-45. (Pubitemid 40143631)
21. Ashida Y, Saijoh T, Kuriki H, et al. Pharmacological profile of AA-861, a lipoxygenase inhibitor. Prostaglandins 1983;26:955-970 (Pubitemid 14165834)
22. Obata T, Okada Y, Motoishi M, et al. In vitro antagonism of ONO-1078, a newly developed anti-asthma agent, against peptide leukotorienes in isolated guinea pig tissues. Japan J Pharmacol 1992;60:227-237
23. Satoh H, Guth PH, Grossman MI. Role of food in gastrointestinal ulceration produced by indomethacin in the rat. Gastroenterology 1982;83:210-215
24. Satoh H, Shiotani S, Otsuka N. Indigestible solid components of food and intestinal hyper-motilities play an important role in the formation of intestinal ulcers induced by indomethacin in cats and dogs. Gastroenterology 2006;130(Suppl 2):A-271.
25. Anthony A, Pounder RE, Dhillon AP, et al. Vascular anatomy defines site of indomethacin induced jejunal ulceration along the mesenteric margin. Gut 1997;41:763-770 (Pubitemid 28023178)
26. Kunikata T, Tanaka A, Miyazawa T, et al. 16,16-Dimethyl prostaglandin E2 inhibits indomethacin-induced small intestinal lesions through EP3 and EP4 receptors. Dig Dis Sci 2002;47:894-904.
27. Chutkan R, Toubia N. Effect of nonsteroidal anti-inflammatory drugs on the gastrointestinal tract: diagnosis by wireless capsule endoscopy. Gastrointest Endoscopy Clin N Am 2004;14:67-85. (Pubitemid 38234306)
28. Ishihara Y, Okabe S. Effects of cholestyramine and synthetic hydrotalcite on acute gastric or intestinal lesion formation in rats and dogs. Dig Dis Sci 1981;26:553-560 (Pubitemid 11078777)
29. Reuter BK, Davies NM, Wallace JL. Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology 1997;112:109-117
30. Duggan DE, Hooke KF, Noll RM, et al. Enterohepatic circulation of indomethacin and its role in intestinal irritation. Biochem Pharmacol 1975;25:1749-1754
31. Nishio H, Hayashi Y, Terashima S, et al. Protective effect of pranlukast, a cysteinylleukotriene receptor 1 antagonist, on indomethacin-induced small intestinal damage in rats. Inflammopharmacology 2007;15:266-272 (Pubitemid 351196135)
32. Holme G, Brunet G, Piechuta H, et al. The activity of synthetic leukotriene C-1 on guinea pig trachea and ileum. Prostaglandins 1980;20:717-728 (Pubitemid 11176176)
33. Yoshikawa S, Fukunaga Y, Takeuchi T, et al. Modulation of acetylcholine release from the myenteric plexus of guinea-pig ileum by 5-lipoxygenase metabolites of arachidonic acid. Eur J Pharmacol 1993;239:261-264 (Pubitemid 23240173)
34. 4 in the intestine. Hepato-gastroenterol 1988;35:87-90.
35. Garcia M, Nakabayashi T, Mochiki E, et al. Pranlukast, a leukotriene receptor antagonist, prolongs the duration of themigratingmotor complex in dogs. Dig Dis Sci 2004;49:1228-1235 (Pubitemid 39178094)
36. Sanders KM. Evidence that prostaglandins are local regulatory agents in canine ileal circular muscle. Am J Physiol 1984;246:G361-71.
37. Kuroda M, Yoshida N, Ichikawa H, et al. Lansoprazole, a proton pump inhibitor, reduces the severity of indomethacin-induced rat enteritis. Int J Mol Med 2006;17:89-93.
38. Pozzoli C, Menozzi A, Grandi D, et al. Protective effects of proton pump inhibitors against indomethacin-induced lesions in the rat small intestine. Naunyn Schmiedbergs Arch Pharmacol 2007;374:283-291 (Pubitemid 46089466)